The FDA issued an Ocaliva FDA drug safety alert in December 2024 that may result in another Ocaliva label change.  This alert was for cases of liver transplants and liver-related deaths among patients without pre-existing cirrhosis who used Ocaliva as a treatment for primary biliary cholangitis (PBC). To provide context for this most recent … [Read more...]